Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial | NeoGenomics Laboratories

Publication date

Mon, 05/12/2025 - 12:00

Category

Year

External link

https://pmc.ncbi.nlm.nih.gov/articles/PMC12067755/#Sec2